Clinical Trial News and Research

RSS

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.

23 Sep 2013

Packaging Coordinators, Inc., to exhibit service offerings at CPhI 2013

Packaging Coordinators, Inc. (PCI), a global supplier of pharmaceutical commercial packaging solutions and clinical trials services is pleased to announce that it will be exhibiting its full range of services on booth 41M15 at CPhI Worldwide. Exhibiting for the first time as Packaging Coordinators, inc. since May 2013 when AndersonBrecon merged with and operated as Frazier Healthcare’s portfolio company, PCI, the company is now one of the largest suppliers of packaging supply services to the pharmaceutical industry and will be demonstrating its capabilities in clinical trials, in laboratory services and commercial services for pharmaceutical and biopharmaceutical customers.

From Packaging Coordinators Inc. (PCI) 23 Sep 2013

Researchers conduct study to determine best option for pregnancies complicated by poor fetal growth

Researchers are conducting a clinical trial to help determine the best timing of delivery in preterm pregnancies complicated by poor fetal growth.

23 Sep 2013

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Ablynx and AbbVie today announced that they have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

23 Sep 2013

Cardinal Health grants funds to support Tissue Engineering Program at Nationwide Children's Hospital

Cardinal Health recently donated $1 million to Nationwide Children's Hospital to help advance the work and research of its Tissue Engineering Program.

23 Sep 2013

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium.

21 Sep 2013

New cellular switch could eventually inhibit growth of aggressive malignant brain tumor

Researchers at UT Southwestern Medical Center have identified a cellular switch that potentially can be turned off and on to slow down, and eventually inhibit the growth of the most commonly diagnosed and aggressive malignant brain tumor.

21 Sep 2013

Equatorial Guinea presents design for malaria vaccine trial

Equatorial Guinea's Ministry of Health and Social Security recently presented a design for a malaria vaccine trial as part of the government's efforts to improve the country's public health.

21 Sep 2013

Scientists aim at protecting adults from virulent strain of avian influenza virus

Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.

20 Sep 2013

Clinical trial by Moffitt to reduce risk of prostate cancer in black men

Prostate cancer kills more African-American and black men than any other group. Yet, according to a new review published by Moffitt Cancer Center researchers, there is a significant lack of clear and consistent screening and early detection guidelines or prevention strategies.

20 Sep 2013

Hormone replacement therapy formulations may cause different risks for stroke, heart attack

Post-menopausal women whose doctors prescribe hormone replacement therapy for severe hot flashes and other menopause symptoms may want to consider taking low doses of Food and Drug Administration-approved bioidentical forms of estrogen or getting their hormones via a transdermal patch.

20 Sep 2013

LCT successfully implants first patient with potential Parkinson's disease treatment

Living Cell Technologies Limited today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL – a potential treatment for Parkinson's disease.

20 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

Wearing back braces prevents need for spinal correction surgery in children with AIS

A multi-center study led by University of Iowa researchers to determine whether wearing back braces would prevent the need for spinal correction surgery in children with adolescent idiopathic scoliosis (AIS) was cut short when early results were overwhelmingly in favor of bracing.

19 Sep 2013

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Omeros Corporation today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

19 Sep 2013

Decompression surgery: An effective procedure for cervical spondylotic myelopathy

In a world-first, decompression surgery has been shown to be an effective procedure to treat cervical spondylotic myelopathy - a common progressive, degenerative disease of the spine that can lead to paralysis - according to the results of a multi-centre clinical trial published today.

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Results of a Pfizer-commissioned study published this month in Annals of Internal Medicine reveal that smokers with a past or present diagnosis of major depressive disorder (MDD)* taking varenicline had a significantly higher likelihood of quitting smoking (after 12 weeks and at 52 weeks) than those who were given a placebo.

18 Sep 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

Test evaluates benefits of fully dissolvable and temporary drug eluting stent to open heart artery blockages

The Mount Sinai Medical Center is participating in the nationwide ABSORB III clinical trial testing the performance and potential clinical benefits of a fully dissolvable and temporary drug eluting stent to open heart artery blockages.

18 Sep 2013

Clinical Trial News and Research

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Packaging Coordinators, Inc., to exhibit service offerings at CPhI 2013

Researchers conduct study to determine best option for pregnancies complicated by poor fetal growth

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Cardinal Health grants funds to support Tissue Engineering Program at Nationwide Children's Hospital

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

New cellular switch could eventually inhibit growth of aggressive malignant brain tumor

Equatorial Guinea presents design for malaria vaccine trial

Scientists aim at protecting adults from virulent strain of avian influenza virus

Clinical trial by Moffitt to reduce risk of prostate cancer in black men

Hormone replacement therapy formulations may cause different risks for stroke, heart attack

LCT successfully implants first patient with potential Parkinson's disease treatment

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Wearing back braces prevents need for spinal correction surgery in children with AIS

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Decompression surgery: An effective procedure for cervical spondylotic myelopathy

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Test evaluates benefits of fully dissolvable and temporary drug eluting stent to open heart artery blockages

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer